日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center

脊索瘤的免疫疗法和酪氨酸激酶抑制剂:来自欧洲罕见成人实体肿瘤参考网络成员中心的真实世界数据研究

Balsa, Mario; Torrent, Francesc; Pérez, Diana; Ruiz, Alejandro; Viñals, Joan Maria; Pablos, Oscar; Fontalva, Maria; Portabella, Federico; Lozano, Alicia; González-Viguera, Javier; Narváez, Jose Antonio; Hernández, Javier; Sardiñas, Juan Carlos; Sanjuan, Xavier; Ippoliti, Gianni; Comabella, Ma Rosa; Sala, Rosó; García Del Muro, Xavier; Jiménez, Laura; Martin-Liberal, Juan

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma

一项针对晚期黑色素瘤、皮肤鳞状细胞癌、头颈部鳞状细胞癌或腺样囊性癌患者的瘤内注射CV8102的I期研究

Eigentler, Thomas; Thomas, Ioannis; Samoylenko, Igor; Erdmann, Michael; Heinzerling, Lucie; Ochsenreither, Sebastian; Krauss, Jürgen; Oberoi, Arjun; Robert, Caroline; Lebbe, Celeste; Martin-Liberal, Juan; Koch, Lukas; Richtig, Erika; Terheyden, Patrick; Weishaupt, Carsten; Mohr, Peter; Semiletova, Yulia; Perez, Casilda Llacer; Brossart, Peter; Bauernfeind, Franz Georg; Fluck, Michael; Poltoratskiy, Artem; Sekacheva, Marina; Soria, Ainara; Schmitt-Bormann, Beate; Gonzalez, Marina; Heß, Jana; Wengenmayer, Peter; Seibel, Tobias; Koch, Sven D; Quintini, Gianluca; Codó, Paula; Falk, Martin; Schönborn-Kellenberger, Oliver; Gnad-Vogt, Ulrike

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors

ICOS激动剂feladilimab治疗晚期实体瘤患者的首次人体I期研究

Maio, Michele; Moreno, Victor; Martin-Liberal, Juan; Opdam, Frans; Hansen, Aaron; Bauer, Todd M; Le Tourneau, Christophe; Italiano, Antoine; Rischin, Danny; Ellis, Catherine; Turner, David; Yadavilli, Sapna; Zhou, Helen; Hirschfeld, Steven; Ballas, Marc; Diaz-Padilla, Ivan; Angevin, Eric

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

FAZ053(一种抗程序性死亡配体1 (抗PD-L1) 单克隆抗体)单药治疗以及与斯帕塔利珠单抗 (抗PD-1) 联合治疗晚期恶性肿瘤患者的首次人体研究

Janku, F; Tan, D S P; Martin-Liberal, J; Takahashi, S; Geva, R; Gucalp, A; Razak, A; Kan, R; Reiners, R; Mataraza, J; Szpakowski, S; Subramanian, K; Chen, X; Lai, C; Bedard, P L

Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

癌细胞可塑性决定了皮肤鳞状细胞癌对免疫疗法的反应

Laura Lorenzo-Sanz ,Marta Lopez-Cerda ,Victoria da Silva-Diz ,Marta H Artés ,Sandra Llop ,Rosa M Penin ,Josep Oriol Bermejo ,Eva Gonzalez-Suarez ,Manel Esteller ,Francesc Viñals ,Enrique Espinosa ,Marc Oliva ,Josep M Piulats ,Juan Martin-Liberal ,Purificación Muñoz

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

Encorafenib 和 binimetinib 联合放疗治疗 BRAFV600 突变型黑色素瘤伴脑转移患者(E-BRAIN/GEM1802 II 期研究)

Márquez-Rodas, Iván; Álvarez, Ana; Arance, Ana; Valduvieco, Izaskun; Berciano-Guerrero, Miguel-Ángel; Delgado, Raquel; Soria, Ainara; Lopez Campos, Fernándo; Sánchez, Pedro; Romero, Jose Luis; Martin-Liberal, Juan; Lucas, Anna; Díaz-Beveridge, Roberto; Conde-Moreno, Antonio-José; Álamo de la Gala, Maria Del Carmen; García-Castaño, Almudena; Prada, Pedro José; González Cao, María; Puertas, Enrique; Vidal, Joana; Foro, Palmira; Aguado de la Rosa, Carlos; Corona, Juan Antonio; Cerezuela-Fuentes, Pablo; López, Paco; Luna, Pablo; Aymar, Neus; Puértolas, Teresa; Sanagustín, Pilar; Berrocal, Alfonso

IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma

IGF1R信号通过ITGAV诱导皮肤癌中的上皮-间质可塑性

Marta Lopez-Cerda ,Laura Lorenzo-Sanz ,Victoria da Silva-Diz ,Sandra Llop ,Rosa M Penin ,Josep Oriol Bermejo ,Richard de Goeij-de Haas ,Sander R Piersma ,Thang V Pham ,Connie R Jimenez ,Juan Martin-Liberal ,Purificación Muñoz

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

基于病毒载体的个性化疫苗I期试验可诱导强烈的肿瘤新抗原特异性抗肿瘤T细胞反应

D'Alise, Anna Morena; Leoni, Guido; Cotugno, Gabriella; Siani, Loredana; Vitale, Rosa; Ruzza, Valentino; Garzia, Irene; Antonucci, Laura; Micarelli, Elisa; Venafra, Veronica; Gogov, Sven; Capone, Alessia; Runswick, Sarah; Martin-Liberal, Juan; Calvo, Emiliano; Moreno, Victor; Symeonides, Stefan N; Scarselli, Elisa; Bechter, Oliver

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

针对SWI/SNF复合物改变的晚期肿瘤中肿瘤浸润淋巴细胞的II期临床方案研究:TILTS研究

Martin-Liberal, Juan; Garralda, Elena; García-Donas, Jesús; Soto-Castillo, Juan José; Mussetti, Alberto; Codony, Carles; Martin-Lluesma, Silvia; Muñoz, Susana; Galvao, Vladimir; Lostes, Julia; Rotxes, Marta; Prat-Vidal, Cristina; Palomero, Jara; Muñoz, Ainhoa; Moreno, Rafael; García Del Muro, Xavier; Sureda, Anna; Alemany, Ramon; Gros, Alena; Piulats, Josep Maria

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

一项针对晚期实体瘤患者的 1/2 期研究,评估 PD-L1 抑制剂 BGB-A333 单药治疗以及与 PD-1 抑制剂替雷利珠单抗联合治疗的疗效。

Desai, Jayesh; Fong, Peter; Moreno, Victor; Frentzas, Sophia; Meniawy, Tarek; Markman, Ben; Voskoboynik, Mark; Rahman, Tahmina; Budha, Nageshwar; Wu, John; Marlow, Jin; Yang, Silu; Calvo, Emiliano; Martin-Liberal, Juan